Robeco Institutional Asset Management B.V. Boosts Holdings in Insulet Corporation (NASDAQ:PODD)

Robeco Institutional Asset Management B.V. increased its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 257.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 84,708 shares of the medical instruments supplier's stock after buying an additional 61,031 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.12% of Insulet worth $22,245,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in PODD. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. purchased a new position in Insulet in the fourth quarter valued at $42,000. SRS Capital Advisors Inc. grew its stake in Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 56 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in Insulet by 553.1% during the 1st quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after purchasing an additional 177 shares during the period. Finally, Assetmark Inc. increased its holdings in Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 246 shares during the period.

Insider Activity at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.39% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PODD. The Goldman Sachs Group initiated coverage on Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective for the company. Oppenheimer lifted their price target on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Royal Bank Of Canada assumed coverage on shares of Insulet in a research report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price objective on the stock. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Finally, Raymond James Financial reaffirmed an "outperform" rating and set a $360.00 price objective (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average price target of $321.00.

Insulet Stock Up 1.0%

Insulet stock opened at $313.08 on Friday. The company has a market capitalization of $22.03 billion, a P/E ratio of 56.31, a PEG ratio of 2.79 and a beta of 1.37. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. Insulet Corporation has a fifty-two week low of $173.00 and a fifty-two week high of $329.33. The stock has a 50-day simple moving average of $297.69 and a 200-day simple moving average of $277.64.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The firm's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.73 earnings per share. Equities research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.